Search

Displaying results 3321 - 3330 of 9333 in total
  1. Drug

    XEN-2174

    go.drugbank.com/drugs/DB05012
    Experimental

    NET is the primary mechanism regulating the biological effects of norepinephrine (NE) on the body. … In episodes of pain, inhibition of NET by XEN-2174 elevates the levels of NE leading to the activation of inhibitory pathways preventing pain signals from reaching the brain.

  2. Drug

    Romiplostim

    go.drugbank.com/drugs/DB05332
    ApprovedInvestigational

    Romiplostim is a thrombopoiesis stimulating dimer Fc-peptide fusion protein (peptibody) to increase platelet production through activation of the thrombopoietin receptor. … Each subunit consists of an IgG1 Fc carrier domain that is covalently attached to a polypeptide sequence that contains two binding domains to interact with thrombopoietin receptor c-Mpl.

  3. Drug

    Toloxatone

    go.drugbank.com/drugs/DB09245
    Experimental

    Toloxatone is an antidepressant agent, the first ever use of which was in France, 1984. It acts as a selective and reversible inhibitor of monoamine oxidase-A (MOA) [L1388].

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
  4. Drug

    Buformin

    go.drugbank.com/drugs/DB04830
    ApprovedWithdrawn

    Buformin is an anti-diabetic drug of the biguanide class, chemically related to metformin and phenformin. … It was withdrawn from the market in most countries due to a high risk of causing lactic acidosis.

  5. Drug

    YKP-1358

    go.drugbank.com/drugs/DB06109
    Experimental

    In addition, the YKP1358 pharmacological profile suggests a very low potential for extrapyramidal side effects. … YKP1358 is a novel serotonin (5-HT2A) and dopamine (D2) antagonist that has demonstrated potent activity in animals that relates to both positive and negative symptoms of schizophrenia.

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
  6. Drug

    Amolimogene bepiplasmid

    go.drugbank.com/drugs/DB04904
    Investigational

    Amolimogene is an investigational therapeutic designed to specifically augment the body's defensive response to human papillomavirus (HPV). … Amolimogene was biologically engineered as a targeted therapy for the treatment of cervical dysplasia.

  7. Drug

    Bunamiodyl

    go.drugbank.com/drugs/DB04814
    ApprovedWithdrawn

    Withdrawn from the Canadian, US, and UK markets in 1963 due to nephropathy.

  8. Drug

    Dantron

    go.drugbank.com/drugs/DB04816
    ApprovedWithdrawn

    Withdrawn from the Canadian, US, and UK markets in 1998 due to genotoxicity.

  9. Drug

    Oxeladin

    go.drugbank.com/drugs/DB04822
    ApprovedWithdrawn

    Withdrawn from the Canadian, US, and UK markets in 1976 due to carcinogenicity.

  10. Drug

    Alacepril

    go.drugbank.com/drugs/DB21364
    Experimental

    The usage of the INN stem '-pril' in the name indicates that Alacepril is a angiotensin-converting enzyme inhibitor. Alacepril has a monoisotopic molecular weight of 406.16 Da.

    Categories: Agents Acting on the Renin-Angiotensin System